Literature DB >> 15871682

GDNF delivery using human neural progenitor cells in a rat model of ALS.

Sandra M Klein1, Soshana Behrstock, Jacalyn McHugh, Kristin Hoffmann, Kyle Wallace, Masatoshi Suzuki, Patrick Aebischer, Clive N Svendsen.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of spinal cord, brainstem, and cortical motor neurons. In a minority of patients, the disease is caused by mutations in the copper (2+)/zinc (2+) superoxide dismutase 1 (SOD1) gene. Recent evidence suggests that astrocytes are dysfunctional in ALS and may be a critical link in the support of motor neuron health. Furthermore, growth factors, such as glial cell line-derived neurotrophic factor (GDNF), have a high affinity for motor neurons and can prevent their death following various insults, but due to the protein's large size are difficult to directly administer to brain. In this study, human neural progenitor cells (hNPC) isolated from the cortex were expanded in culture and modified using lentivirus to secrete GDNF (hNPC(GDNF)). These cells survived up to 11 weeks following transplantation into the lumbar spinal cord of rats overexpressing the G93A SOD1 mutation (SOD1 (G93A)). Cellular integration into both gray and white matter was observed without adverse behavioral effects. All transplants secreted GDNF within the region of cell survival, but not outside this area. Fibers were seen to upregulate cholinergic markers in response to GDNF, indicating it was physiologically active. We conclude that genetically modified hNPC can survive, integrate, and release GDNF in the spinal cord of SOD1 (G93A) rats. As such, they provide an interesting source of cells for both glial replacement and trophic factor delivery in future human clinical studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15871682     DOI: 10.1089/hum.2005.16.509

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  88 in total

1.  Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis.

Authors:  Antonio Hayes-Punzo; Patrick Mulcrone; Michael Meyer; Jacalyn McHugh; Clive N Svendsen; Masatoshi Suzuki
Journal:  Amyotroph Lateral Scler       Date:  2012-03-13

2.  Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier.

Authors:  Fumitaka Shimizu; Yasuteru Sano; Kazuyuki Saito; Masa-aki Abe; Toshihiko Maeda; Hiroyo Haruki; Takashi Kanda
Journal:  Neurochem Res       Date:  2011-10-16       Impact factor: 3.996

Review 3.  Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

Authors:  Rachna S Pandya; Lilly L J Mao; Edward W Zhou; Robert Bowser; Zhenglun Zhu; Yongjin Zhu; Xin Wang
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-03

4.  Neurogenic responses to amyloid-beta plaques in the brain of Alzheimer's disease-like transgenic (pPDGF-APPSw,Ind) mice.

Authors:  Li Gan; Shuhong Qiao; Xun Lan; Liying Chi; Chun Luo; Lindsey Lien; Qing Yan Liu; Rugao Liu
Journal:  Neurobiol Dis       Date:  2007-08-21       Impact factor: 5.996

Review 5.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

6.  Acute glial activation by stab injuries does not lead to overt damage or motor neuron degeneration in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis.

Authors:  Masatoshi Suzuki; Sandra Klein; Elizabeth A Wetzel; Michael Meyer; Jacalyn McHugh; Craig Tork; Antonio Hayes; Clive N Svendsen
Journal:  Exp Neurol       Date:  2009-12-11       Impact factor: 5.330

7.  Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis.

Authors:  Nicole L Nichols; Genevieve Gowing; Irawan Satriotomo; Lisa J Nashold; Erica A Dale; Masatoshi Suzuki; Pablo Avalos; Patrick L Mulcrone; Jacalyn McHugh; Clive N Svendsen; Gordon S Mitchell
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

Review 8.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.

Authors:  G Yacila; Y Sari
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 10.  Stem cells in human neurodegenerative disorders--time for clinical translation?

Authors:  Olle Lindvall; Zaal Kokaia
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.